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Abstract 
This case study discusses in detail for the first time the diagnosis and management of a case 
of leishmaniosis in a dog imported to Australia. The dog presented with epistaxis and a non-
regenerative anaemia five years after being imported from Europe. Protozoa were identified 
within macrophages in bone marrow and splenic cytology. A Leishmania indirect fluorescent 
antibody test was performed and was positive while an Ehrlichia canis antibody test was 
negative. Polymerase chain reaction of the ITS-1 and ITS-2 regions of skin, lymph node, 
spleen and bone marrow were all positive for Leishmania infantum. The dog was treated with 
amphotericin B with a strong clinical response. The importance of thorough diagnostics in 
non-endemic areas, particularly Australia, is discussed. Treatment with amphotericin B is 
discussed. Vigilance, disease reporting and response frameworks are recommended for non-
endemic areas. 
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Introduction 
Canine leishmaniosis is a zoonotic tropical disease with a widespread global distribution 
(Solano-Gallego et al., 2009) and an expanding geographical range (Gonzalez et al., 
2010 and Gramiccia, 2011). It is a significant zoonotic disease with World Health 
Organisation global burden disease estimates placing Leishmania second for mortality and 
fourth for morbidity amongst human tropical diseases (Mathers et al., 2007). Diagnostic 
options for canine leishmaniosis have increased in number and accuracy in recent years but 
definitive diagnosis in dogs still requires several, concordant test results (Solano-Gallego et 
al., 2009 and Gramiccia, 2011). Opinions on optimal and ethical treatment vary with 
compulsory culling still current in some countries, whereas increasingly sophisticated 
treatments are employed elsewhere (Gramiccia, 2011 and Dantas-Torres et al., 2012). While 
some question the ability to truly cure canine leishmaniosis (Ribeiro et al., 2008, Manna et 
al., 2009 and Torres et al., 2011) clinical cures can be achieved with some dogs no longer 
infectious through their biological vectors ( da Silva et al., 2012). 
 
In Australia there is no recognised endemic zoonotic Leishmania species present. A small 
number of cases have been recorded in imported dogs but to date none of these have been 
published. An endemic Australian Leishmania species in a captive population of red 
kangaroos (Macopus rufus) (Rose et al., 2004) and in several species of wild macropods 
(Dougall et al., 2009) has been discovered recently. This creates a need for rigorous 
diagnostic testing to identify the causative species if leishmaniosis is suspected in Australia. 
While phlebotomine sandflies are present in Australia there are no known competent 
biological vectors of the non-Australian Leishmania species present. A day-flying midge, 
species Forcipomyia (Lasiohelea) spp., has been implicated as the vector for endemic 
Australian Leishmania ( Dougall et al., 2011) and this is the first non-sandfly insect strongly 
implicated as a natural vector of any Leishmania species. In light of these findings a thorough 
disease plan should be in place for suspected cases of Leishmania in Australia; including 
comprehensive diagnostic testing, clear treatment goals, monitoring of response to treatment 
and measures to minimise the risk of transmission to other dogs and people. While Australia 
is in a unique situation with regards to Leishmania, many considerations are likely applicable 
to other extralimital areas. 
 
Case report 
A nine year old female neutered husky dog was presented with a three month history of 
bilateral mucopurulent nasal discharge, which had progressed to minor epistaxis three weeks 
prior to presentation, and major epistaxis three days prior to presentation. Previous medical 
history included three years of presumed atopic dermatitis which had been treated with 
courses of prednisolone and cephalexin. The dog had recently developed bilateral 
symmetrical alopecia and calcinosis cutis, attempts to withdraw the prednisolone had resulted 
in collapse 48 h later. The dog was born in Portugal and had lived in the UK, during which 
time the dog had travelled back and forth from Portugal to the UK. In 2007 at the age of five 
the dog was emigrated to Australia and, after the required period of quarantine, had moved to 
a Brisbane suburb and resided there for the last four years, with no history of wider travel 
within Australia. Serological testing for Leishamania via IFAT or ELISA was required prior 
to import to Australia at this time. The precise test information for this dog is not known but 
presumably the result was negative. 
 
Clinical examination revealed no obvious structural, pigmentation or sensation changes 
around the nasal cavity with normal symmetrical airflow. The mucous membranes were pale 
with a rapid refill. There was widespread non-pruritic symmetrical alopecia with calcinosis 
cutis and small open sores. Hepatomegaly and mild peripheral lymphadenopathy were 
appreciated. 
 
An abdominal ultrasound showed a large hyperechoic liver containing a cavitated and 
partially mineralised mass, suspected to be a benign lesion, while the adrenal glands were 
small and inconspicuous. A biochemistry panel was performed (Chem17 + lytes4, Catalyst 
Dx; IDEXX) which revealed a hepatopathy with an ALP 1514 U/L (reference interval (RI): 
23–212 U/L), ALT 143 U/L (RI: 10–100 U/L), GGT 42 U/L (RI: 0–7 U/L), a mild 
hyperglobulinemia at 46 g/L (RI: 25–45 g/L) and a slightly decreased creatinine at 42 μmol/L 
(RI: 44–159 μmol/L). An activated clotting time (VetScan I-STAT; Abaxis) was 106 s (RI: 
90–130 s). The PCV was 15% (RI: 35–57%) while a smear examination suggested a non-
regenerative anaemia with morphologically normal red and white cells. A single macrophage 
at the feathered edge of a blood smear was observed with suspected intracytoplasmic 
organisms. Cystocentesis was performed and the urine had a specific gravity of 1.013 with an 
active sediment from which multisensitive Escherichia coli was isolated. 
 
The dog was sedated for bone marrow aspiration and a nasal computed tomograph. Bone 
marrow cytology showed adequate populations of all cell-line precursors with approximately 
10% of cells present being macrophages with the cytoplasm distended by populations of 
protozoa with 2 μm diameters, a dark nucleus, a single bar-shaped kinetoplast and pale-blue 
cytoplasm. Nasal CT was unremarkable with no mass effect or erosive process detected. 
Following notification of and discussion with the Department of Agriculture, Forestry and 
Fisheries Queensland, extensive sampling was performed to allow confirmation of the 
diagnosis prior to treatment. This included collection of multiple aliquots of EDTA blood and 
serum, skin punch biopsies, skin scrapes, thick and thin smears of splenic aspirates and 
lymph node core biopsies. These samples were tested at the Australian Animal Health 
Laboratory and Murdoch University. Protozoal organisms were identified on cytology of the 
bone marrow and in the splenic aspirates (Fig. 1). Histology of the skin and lymph node did 
not identify any organisms. A commercially available (VRMD, 2011) Leishmania infantum 
indirect fluorescent antibody test (IFAT), considered genus specific (OIE, 2008), was 
performed and was positive at 1:6400 and negative at 1:12,800 indicating a high Leishmania 
antibody titre. An Ehrlichia canis antibody test (Protatek immunofluorescence antibody slide 
test) was negative. PCR analysis using the ribosomal ITS-1 and ITS-2 regions (Tai et al., 
2000) was performed on the skin, popliteal lymph node, peripheral blood and bone marrow 
samples. All samples were positive by PCR and sequenced nucleotides were found to be a 
100% match with published sequences of L. infantum (NCBI Accession numbers 
AJ634355/AJ634339). 
The affected dog had three companions that closely cohabited in an outdoors run with close 
contact during the day and night with biting insects known to be present. All three companion 
dogs, two huskies and a malamute, were negative on L. infantum IFAT. 
 
At 28 days following initial presentation treatment was begun and a deltamethrin-
impregnated collar was obtained (Scalibor; Intervet). Amphotericin B lipid complex was 
given intravenously at 50 mg per dose (approximately 2.5 mg/kg) diluted to 1 mg/ml in 5% 
dextrose in water and given over one hour. Creatinine, ALT and electrolytes were monitored, 
a 10 ml/kg fluid bolus was given and maropitant (Cerenia; Zoetis) was administered prior to 
each treatment. An acute increase in ALT up to 702 U/L was recorded following the second 
treatment with normal bile acid stimulation test results. This reduced rapidly with supportive 
care including SAMe (Denosyl; Ceva) and a short treatment delay. Following the fourth dose 
acute kidney injury was indicated by a creatinine of 872 μmol/L, resulting in seven days 
hospitalisation on fluid therapy prior to discharge for home care with an esophagostomy tube 
placed. Further treatment was deferred for 53 days after which time creatinine was back 
within normal limits and treatment was resumed with a similar protocol to the initial round of 
treatment, except daily doses of 25 mg amphotericin B were given for four consecutive days. 
This treatment was tolerated well with a moderate increase in ALT to 384 U/L observed but 
no renal compromise or clinically apparent side effects noted. The total dose of amphotericin 
B given was approximately 15 mg/kg. 
 
One month following completion of the treatment blood PCR was negative for L. infantum 
and allopurinol was started at a dose of 15 mg/kg orally twice daily. 
Discussion 
Leishmaniosis presents a major diagnostic and management challenge wherever it occurs. In 
endemic areas the approach to this disease varies widely and remains contentious (Dantas-
Torres et al., 2012). In non-endemic areas there are sporadic case reports of disease 
(Slappendel and Teske, 1999) but even where travel-related disease is relatively common, 
such as in the United Kingdom, the disease is often not closely monitored, is likely under-
reported and the risks of transmission are poorly understood (Shaw et al., 2009). 
 
In this case thorough diagnostics excluded potential alternative infections, such as E. canis 
which can cross react serologically (Ferreira et al., 2007 and Marcondes et al., 2011), 
primarily through the use of PCR analysis. Appropriate testing will depend upon geographic 
location and should be conducted in under the consultation or supervision of the relevant 
government authority as Leishmania is an OIE-listed disease (OIE, 2013). Monitoring of 
disease incidence allows protection of public health and response to changes in the disease 
prevalence or transmission. Where leishmaniosis is not a notifiable disease its prevalence is 
underreported (Shaw et al., 2009) and the risk of failing to detect a new or low density 
competent vector is increased. 
 
The decision to treat is controversial. In this case treatment was performed due to the lack of 
known local vectors which made epidemic veterinary disease and zoonotic disease highly 
unlikely. 
 
Amphotericin B is not recommended in endemic areas due to concerns about side effects and 
induction of human resistance. It was used in this case because of its excellent availability 
and low cost compared to other suitable agents in Australia, the low risk of development of 
resistance, the low likelihood of zoonotic transmission and the patients’ clinical suitability for 
this medication with a low serum creatinine prior to treatment. 
 
Please consult the supplementary material provided electronically with this article for in 
depth discussion and review of the literature discussing the major issues of canine 
leishmaniosis in extralimital areas; including diagnosis, the decision to treat, the risks of 
transmission, treatment options and disease monitoring. The decisions made in this specific 
case are further discussed in this material. 
 
In conclusion the increasing incidence of leishmaniosis in non-endemic areas is challenging 
owners, veterinarians and government authorities. These authors identify a need for clear, 
locally relevant guidelines directing diagnosis, treatment and management of suspected cases. 
This case report provides an example of such case management and highlights issues of 
particular relevance to Australia, such as the local status of Leishmania, incidence of canine 
travel to endemic areas, local climate and possible local vectors. These guidelines would be 
recommended for all governments in non-endemic Leishmania areas. 
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Figure 1. Cytology of a splenic macrophage containing protozoal organisms within the 
cytoplasm. Organisms are approximately 2 μm in diameter, with a blue nucleus, a single dark 
purple kinetoplast and a pale blue cytoplasm. Bar = 10 μm. 
 
 
 
